One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
MediciNova, Inc.
MNOV · NGM · Healthcare · Biotechnology
Current price
$1.40
52-week range
$1.17 - $3.90
Market cap
$68.91M
Balance sheet
Healthy
-10.19x Concerning
Net cash $25.30M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 187.7% last year.
- Risk Return on equity was -25.6% last year — the company lost money on shareholders' equity.
What this company does
MediciNova, Inc.
MediciNova develops medicines for serious illnesses, with its main money coming from research and development for drugs like MN-166, which is being tested for diseases like multiple sclerosis. This matters because successful drug development could lead to treatments for patients and significant revenue for the company if the drugs are approved and sold.
How the company got here
MediciNova, Inc. was founded in 2000 with the goal of developing new medicines for serious diseases that lack effective treatments. The company, headquartered in La Jolla, California, has focused on acquiring rights to promising drug candidates, often through partnerships with Japanese pharmaceutical companies. This strategy has allowed MediciNova to build a pipeline of potential therapies without having to discover them from scratch. A key turning point was securing the rights to develop MN-166 (ibudilast) and MN-001 (tipelukast), which have become the company's main focus for treating a variety of challenging conditions.
What it actually does
MediciNova is a biopharmaceutical company, which means it researches, develops, and aims to bring new medicines to market. Instead of selling everyday products, MediciNova works on creating treatments for diseases. They focus on 'small molecule' drugs, which are medications made from chemicals that can enter cells to affect their function. The company's work involves conducting extensive clinical trials (testing in humans) to prove that their drug candidates are safe and effective before they can be approved by regulatory agencies like the FDA.
MN-166 (ibudilast) for Neurological and Other Disorders
This is MediciNova's lead drug candidate, MN-166 (ibudilast), which is an oral medication designed to reduce inflammation and protect nerve cells. It is currently in late-stage clinical trials for serious neurological conditions. These include amyotrophic lateral sclerosis (ALS), a progressive disease of nerve cells; multiple sclerosis (MS), an autoimmune disease affecting the nervous system; and degenerative cervical myelopathy (DCM), a spinal cord condition. MN-166 is also being investigated for glioblastoma (a type of brain cancer), chemotherapy-induced peripheral neuropathy (nerve damage from cancer treatment), and to help prevent acute respiratory distress syndrome (ARDS), a severe lung condition. [1, 6, 7, 12, 15]
MN-001 (tipelukast) for Fibrotic and Metabolic Disorders
MediciNova is also developing MN-001 (tipelukast), another oral medication that aims to reduce inflammation and fibrosis, which is the formation of scar tissue. This drug candidate is being studied for fibrotic and metabolic disorders. Specifically, it is being tested for nonalcoholic fatty liver disease (NAFLD), a condition where excess fat accumulates in the liver, and hypertriglyceridemia, a condition characterized by high levels of a type of fat in the blood called triglycerides. [2, 4, 8, 10, 11, 12, 15]
What management is betting on now
MediciNova's current strategy is to concentrate its efforts on advancing the development of MN-166 for neurological diseases and MN-001 for fibrotic and metabolic conditions. The company is exploring options to either develop these drug candidates on its own or through collaborations with other companies. MediciNova also plans to seek opportunities to generate value from its other drug candidates as they reach important development milestones. This focused approach aims to maximize the potential of their most promising therapies.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-2.03M
FY2024 Q4
$-1.93M
FY2025 Q1
$-3.78M
FY2025 Q2
$-2.31M
FY2025 Q3
$-1.71M
FY2025 Q4
$-2.02M
FY2026 Q1
$-3.48M
FY2026 Q2
$-1.92M
Revenue
$458.44K
Net income
$-2.31M
Diluted EPS
-0.05
Operating cash flow
$-1.92M
Free cash flow
$-1.92M
Fetching…
Sources
Revenue
$186.98K
Net income
$-2.59M
Diluted EPS
-0.05
Operating cash flow
$-3.47M
Free cash flow
$-3.48M
Fetching…
Sources
Revenue
$409.66K
Net income
$-2.80M
Diluted EPS
-0.05
Operating cash flow
$-2.02M
Free cash flow
$-2.02M
Fetching…
Sources
Revenue
$123.32K
Net income
$-3.05M
Diluted EPS
-0.06
Operating cash flow
$-1.70M
Free cash flow
$-1.71M
Fetching…
Sources
Revenue
$134.60K
Net income
$-3.28M
Diluted EPS
-0.07
Operating cash flow
$-2.31M
Free cash flow
$-2.31M
Fetching…
Sources
Revenue
—
Net income
$-2.86M
Diluted EPS
-0.06
Operating cash flow
$-3.78M
Free cash flow
$-3.78M
Fetching…
Sources
Revenue
—
Net income
$-2.81M
Diluted EPS
-0.06
Operating cash flow
$-1.93M
Free cash flow
$-1.93M
Fetching…
Sources
Revenue
—
Net income
$-2.85M
Diluted EPS
-0.06
Operating cash flow
$-2.03M
Free cash flow
$-2.03M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.40
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $25.3M - more cash than debt. Interest coverage -10.2x.
Net debt
$-25.30M
Interest coverage
-10.19x
MediciNova, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.
Healthy
Worse cushion
Baseline
Better cushion
MNOV
BASELINE
MediciNova, Inc.
Total debt $117.04K Interest coverage -10.19x This is the baseline the peer rows are being compared against.
What you should know
The case for and against MNOV
1 Reward
1 Risk
Rewards
-
Revenue grew 187.7% last year.
Risks
-
Return on equity was -25.6% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-2.72x
P/B
1.85x
P/S
74.86x
EV/EBITDA
-3.64x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
37.7%
Operating margin
-554.3%
Net margin
0.0%
ROE
-25.6%
ROA
-16.4%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
8.75x
Quick ratio
8.58x
Total debt
$117.04K
Total cash
$25.42M
Growth
How the business has been compounding
Revenue TTM
$1.18M
Revenue 5Y CAGR
-43.6%
EPS TTM
-0.21
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-9.11M
Free CF TTM
$-9.81M
FCF margin
-832.7%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—